.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,908,928

« Back to Dashboard

Claims for Patent: 6,908,928

Title: Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
Abstract:Crystalline monohydrate of (1.alpha.,2.beta.,4.beta.,5.alpha.,7.beta.)-7-[(hydroxydi-2-thienylacetyl) oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0.sup.2,4 ]nonane bromide (tiotropium bromide monohydrate), processes for the preparation thereof, pharmaceutical compositions thereof, and their use.
Inventor(s): Banholzer; Rolf (Stuttgart, DE), Sieger; Peter (Mittelbiberach, DE), Kulinna; Christian (Mainz, DE), Trunk; Michael (Ingelheim, DE), Graulich; Manfred (Waldalgesheim, DE), Specht; Peter (Ober-Hilbersheim, DE), Meissner; Helmut (Ingelheim, DE), Mathes; Andreas (Ockenheim, DE)
Assignee: BI Pharma KG. (Ingelheim, DE)
Application Number:09/961,822
Patent Claims: 1. A pharmaceutical composition comprising: (a) an effective amount of crystalline tiotropium bromide monohydrate having an endothermic peak at 230.degree. C..+-.5.degree. C. occurring during thermal analysis using DSC at a heating rate of 10 K/mm; and (b) a pharmaceutically acceptable excipient.

2. A pharmaceutical composition comprising: (a) an effective amount of crystalline tiotropium bromide monohydrate having an JR spectrum comprising bands at wave numbers 3570, 3410, 3105, 1730, 1260, 1035, and 720 cm.sup.-1 ; and (b) a pharmaceutically acceptable excipient.

3. A pharmaceutical composition comprising: (a) an effective amount of crystalline tiotropium bromide monohydrate having (i) an endothermic peak at 230.degree. C..+-.5.degree. C. occurring during thermal analysis using DSC at a heating rate of 10 K/mm, and (ii) an JR spectrum comprising bands at wave numbers 3570, 3410,3105, 1730, 1260, 1035, and 720 cm.sup.-1 ; and (b) a pharmaceutically acceptable excipient.

4. A pharmaceutical composition comprising: (a) an effective amount of crystalline tiotropium bromide monohydrate having a single monoclinic cell having the following dimensions: a=18.0774 .ANG., b=11.9711 .ANG., c=9.9321 .ANG., .beta.=102.691.degree., and V=2096.96 .ANG..sup.3 ; and (b) a pharmaceutically acceptable excipient.

5. A pharmaceutical composition comprising: (a) an effective amount of crystalline tiotropium bromide monohydrate having (i) an endothermic peak at 230.degree. C..+-.5.degree. C. occurring during thermal analysis using DSC at a heating rate of 10 K/mm, and (ii) a single monoclinic cell having the following dimensions: a=18.0774 .ANG., b=11.9711 .ANG., c=9.9321 .ANG., .beta.=102.691.degree., and V=2096.96 .ANG..sup.3 ; and (b) a pharmaceutically acceptable excipient.

6. A pharmaceutical composition comprising: (a) an effective amount of crystalline tiotropium bromide monohydrate having (i) an IR spectrum comprising bands at wave numbers 3570, 3410, 3105, 1730, 1260, 1035, and 720 cm.sup.-1, and (ii) a single monoclinic cell having the following dimensions: a=18.0774 .ANG., b=11.9711 .ANG., c=9.9321 .ANG., .beta.=102.691.degree., and V=2096.96 .ANG..sup.3 ; and (b) a pharmaceutically acceptable excipient.

7. A pharmaceutical composition comprising: (a) an effective amount of crystalline tiotropium bromide monohydrate having (i) an endothermic peak at 230.degree. C..+-.5.degree. C. occurring during thermal analysis using DSC at a heating rate of 10 K/min, (ii) an JR spectrum comprising bands at wave numbers 3570, 3410, 3105, 1730, 1260, 1035, and 720 cm.sup.-1, and (iii) a single monoclinic cell having the following dimensions: a=18.0774 .ANG., b=11.9711 .ANG., c=9.9321 .ANG., 13.102.691.degree., and V=2096.96 .vertline..sup.3 ; and (b) a pharmaceutically acceptable excipient.

8. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is an inhalable powder.

9. The pharmaceutical composition according to claim 2, wherein the pharmaceutical composition is an inhalable powder.

10. The pharmaceutical composition according to claim 3, wherein the pharmaceutical composition is an inhalable powder.

11. The pharmaceutical composition according to claim 4, wherein the pharmaceutical composition is an inhalable powder.

12. The pharmaceutical composition according to claim 5, wherein the pharmaceutical composition is an inhalable powder.

13. The pharmaceutical composition according to claim 6, wherein the pharmaceutical composition is an inhalable powder.

14. The pharmaceutical composition according to claim 7, wherein the pharmaceutical composition is an inhalable powder.

15. A method for treatment of diseases in which the administration of an anticholinergic agent may have a therapeutic benefit, in a patient in need of such treatment, which method comprises administering the patient an effective amount of crystalline tiotropium bromide monohydrate having an endothermic peak at 230.degree. C..+-.5.degree. C. occurring during thermal analysis using DSC at a heating rate of 10 K/mm.

16. A method for treatment of diseases in which the administration of an anticholinergic agent may have a therapeutic benefit, in a patient in need of such treatment, which method comprises administering the patient an effective amount of crystalline tiotropium bromide monohydrate having an JR spectrum comprising bands at wave numbers 3570, 3410, 3105, 1730, 1260, 1035, and 720 cm.sup.-1.

17. A method for treatment of diseases in which the administration of an anticholinergic agent may have a therapeutic benefit, in a patient in need of such treatment, which method comprises administering the patient an effective amount of crystalline tiotropium bromide monohydrate having (i) an endothermic peak at 230.degree. C..+-.5.degree. C. occurring during thermal analysis using DSC at a heating rate of 10 K/min, and (ii) an JR spectrum comprising bands at wave numbers 3570, 3410, 3105, 1730, 1260, 1035, and 720 cm.sup.-1.

18. A method for treatment of diseases in which the administration of an anticholinergic agent may have a therapeutic benefit, in a patient in need of such treatment, which method comprises administering the patient an effective amount of crystalline tiotropium bromide monohydrate having a single monoclinic cell having the following dimensions: a=18.0774 .ANG., b=11.9711 .ANG., c=9.9321 .ANG., .beta.=102.6910, and V=2096.96 .ANG..sup.3.

19. Crystalline hydrates of tiotropium bromide obtained by a process comprising: (a) dissolving tiotropium bromide in water to obtain a solution; (b) heating the solution of step (a); (c) adding activated charcoal to the heated solution of step (b); (d) removing the activated charcoal from the solution of step (c); and (e) allowing the solution to slowly cool to obtain crystalline hydrates of tiotropium bromide.

20. Crystalline hydrates of tiotropium bromide according to claim 19, wherein the solution of step (a) is heated to more than 50.degree. C.

21. A method for treatment of diseases in which the administration of an anticholinergic agent may have a therapeutic benefit, in a patient in need of such treatment, which method comprises administering the patient an effective amount of crystalline tiotropium bromide monohydrate having (i) an endothermic peak at 230.degree. C..+-.5.degree. C. occurring during thermal analysis using DSC at a heating rate of 10 K/mm, and (ii) a single monoclinic cell having the following dimensions: a=18.0774 .ANG., b=11.9711 .ANG., c=9.9321 .ANG., .beta.=102.691.degree., and V=2096.96 .vertline..sup.3.

22. A method for treatment of diseases in which the administration of an anticholinergic agent may have a therapeutic benefit, in a patient in need of such treatment, which method comprises administering the patient an effective amount of crystalline tiotropium bromide monohydrate having (i) an IR spectrum comprising bands at wave numbers 3570, 3410, 3105, 1730, 1260, 1035, and 720 cm.sup.-1, and (ii) a single monoclinic cell having the following dimensions: a=18.0774 .ANG., b=11.9711 .ANG., c=9.9321 .ANG., .beta.=102.691.degree., and V=2096.96 .ANG..sup.3.

23. A method for treatment of diseases in which the administration of an anticholinergic agent may have a therapeutic benefit, in a patient in need of such treatment, which method comprises administering the patient an effective amount of crystalline tiotropium bromide monohydrate having (i) an endothermic peak at 230.degree. C. .+-.5.degree. C. occurring during thermal analysis using DSC at a heating rate of 10 K/mm, (ii) an IR spectrum comprising bands at wave numbers 3570, 3410, 3105, 1730, 1260, 1035, and 720 cm.sup.-1, and (iii) a single monoclinic cell having the following dimensions: a=18.0774 .ANG., b=11.9711 .ANG., c=9.9321 .ANG., .beta.=102.691.degree., and V=2096.96 .ANG..sup.3.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc